[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580721":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":26,"responsibleParty":58,"collaborators":10,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":10,"studyType":75,"phases":10,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Ente Ospedaliero Ospedali Galliera","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Retrospective",null,"PATIENTS AGED 70 YEARS AND OVER IN FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER",[13],{"name":14,"affiliation":15,"role":16},"Matteo Clavarezza","E.O. Ospedali Galliera","PRINCIPAL_INVESTIGATOR",[18,23],{"name":14,"role":19,"phone":20,"phoneExt":21,"email":22},"CONTACT","010.5634580","+39","matteo.clavarezza@galliera.it",{"name":24,"role":19,"phone":20,"phoneExt":21,"email":25},"Davide S Corradengo","davide.corradengo@galliera.it",[27,46],{"facility":15,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Genova","GE","16128","Italy","IT",{"type":35,"coordinates":36},"Point",[37,38],11.87211,45.21604,{"lat":38,"lon":37},[41,44],{"name":42,"role":19,"phone":43,"phoneExt":10,"email":25},"Davide CORRADENGO","+390105634580",{"name":45,"role":16,"phone":10,"phoneExt":10,"email":10},"Matteo Clavarezza, MD",{"facility":15,"status":47,"city":48,"state":49,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":50,"geoPoint":54,"contacts":55},"NOT_YET_RECRUITING","Genoa","Liguria",{"type":35,"coordinates":51},[52,53],8.94439,44.40478,{"lat":53,"lon":52},[56,57],{"name":24,"role":19,"phone":20,"phoneExt":21,"email":25},{"name":14,"role":16,"phone":10,"phoneExt":10,"email":10},{"type":59,"investigatorFullName":14,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","MD","100580721","colon-erderly-low-dose-100580721",false,"NCT06840977","COLON ERDERLY LOW DOSE","RETROSPECTIVE OBSERVATIONAL STUDY OF CHEMOTHERAPY IN ELDERLY PATIENTS IN THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER","CELOW","Inclusion Criteria:\n\n1. Patients with metastatic colorectal adenocarcinoma not treated with any therapy in the metastatic phase. Previous (neo)-adjuvant treatment with fluoroderivatives with or without Oxaliplatin is permitted.\n2. Age ≥ 70 years\n3. G8 score ≥ 12\n4. Patients with colorectal adenocarcinoma MSS\n5. Patients with BRAF WT colorectal adenocarcinoma\n6. Ability to understand and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with MSI tumours\n2. Patients with BRAF V600E mutated tumours\n3. Patients not eligible for doublet chemotherapy by clinical decision","ALL","70 Years","99 Years",{"count":73,"type":74},51,"ESTIMATED","OBSERVATIONAL","In this retrospective observational study, the case series of patients undergoing first-line treatment for metastatic colorectal adenocarcinoma with doublet fixed-dose and reduced-dose chemotherapy in combination with full-dose monoclonal antibody in patients aged 70 years or older is collected.",[78],"Colon Adenocarcinoma",[80,81,82,83],"metastatic colorectal adenocarcinom","low doses","chemotherapy","monoclonal antibodies","2026-07-15",{"date":86,"type":87},"2026-07-16","ACTUAL",{"date":89,"type":87},"2026-07-07",{"date":91,"type":74},"2027-07-31",{"name":14,"class":6},2]